Eline L. Giraud
Nijmegen, GE, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Exploring the Association Between Intra-Patient Variability in Trough Concentration of Pazopanib and Clinical Outcomes in Renal Cell Carcinoma and Soft Tissue Sarcoma Patients.
Journal: Clinical pharmacology and therapeutics
Published: February 04, 2025
Selecting the Best Pharmacokinetic Models for a Priori Model-Informed Precision Dosing with Model Ensembling.
Journal: Clinical pharmacokinetics
Published: September 06, 2024
Pharmacokinetic exposure and treatment outcomes of lenvatinib in patients with renal cell carcinoma and differentiated thyroid carcinoma.
Journal: Cancer chemotherapy and pharmacology
Published: July 12, 2024
Evaluating the Clinical Impact and Feasibility of Therapeutic Drug Monitoring of Pazopanib in a Real-World Soft-Tissue Sarcoma Cohort.
Journal: Clinical pharmacokinetics
Published: June 24, 2024
Exploring the contribution of genetic variants to high sunitinib exposure in patients with cancer.
Journal: British journal of clinical pharmacology
Published: April 22, 2024
Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology - an analysis of the closed cohorts of a multicentre prospective study.
Journal: British journal of cancer
Published: April 15, 2024
Sunitinib for the treatment of metastatic gastrointestinal stromal tumors: the effect of TDM-guided dose optimization on clinical outcomes.
Journal: ESMO open
Published: February 01, 2024
Results of the first international quality control programme for oral targeted oncolytics.
Journal: British journal of clinical pharmacology
Published: June 22, 2023
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: an update.
Journal: The Lancet. Oncology
Published: April 17, 2023
QT prolongation with anticancer drugs: a multimodal issue - Authors' reply.
Journal: The Lancet. Oncology
Published: November 01, 2022
The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview.
The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview.
Journal: The Lancet. Oncology
Published: February 23, 2022
Last Updated: 09/26/2026